United States · Platforms & data · Barchart

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study -…

Published by Barchart · United States 4 h ago

Read the full article on Barchart Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (news.google.com)

Also worth reading